What challenges exist in targeting HER3 and HER4 in cancer therapy?
One of the main challenges in targeting HER3 and HER4 is their complex biology and the context-dependent nature of their roles in cancer. HER3's lack of intrinsic kinase activity makes it difficult to target directly, requiring combination strategies. Additionally, HER4's dual role as a tumor suppressor and oncogene complicates the development of targeted therapies. Understanding the specific alterations and signaling context in each cancer type is crucial for developing effective treatments.
